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Abstract 
Background and objective: Metabolic syndrome is a group of characteristics, which include obesity, high 
blood pressure, elevated blood sugar levels, and high triglycerides (fat-like substances in the blood). Having a 
combination of these characteristics increases the risk of developing type 2 diabetes and heart disease. People 
with central obesity have an increased risk for developing metabolic syndrome, type 2 diabetes, and 
cardiovascular disease. However, a substantial number of obese individuals have no other cardiovascular risk 
factors, besides their obesity. C-reactive protein (CRP) is an acute phase protein produced predominantly by 
hepatocytes under the influence of cytokines such as IL -6 and TNF-α. Determination of hs-CRP was carried out 
in this study to discriminate between centrally obese people with and without metabolic syndrome. Patients and 
Methods: One hundred and forty subject with central obesity aged 20-70 years underwent a physical 
examination and laboratory assays to determine the presence of metabolic syndrome (NCEP ATP III criteria). 
The subjects were categorized into metabolic syndrome and non -metabolic syndrome group to decide whether 
CRP has an impact on the development of metabolic syndrome, and further subdivision have made to sub 
classify them to five sub-groups according to the existence of components of metabolic syndrome. Results: 
Mean hs-CRP levels were significantly higher in individuals with central obesity with metabolic syndrome (n = 
101; 72.1%) compared to individuals with central obesity without metabolic syndrome (3.64 mg/L versus 1.75 
mg/L (IQR 1.25-2.24); p < 0.0001). Mean hs-CRP levels increased with increasing number of metabolic 
syndrome components present. In univariable linear regression analyses, hs-CRP was significantly correlated 
positively with body mass index, waist circumference, and atherogenic index, while a significant negative 
correlations was found with HDL-C level. All the obese participants were at risk of cardiovascular events. 
Conclusions: The degree of central obesity (waist circumference) and BMI seemed to be the main determinant 
of an increased hs-CRP level. Serum hs-CRP was significantly correlated with the presence of metabolic 
syndrome; strong relationship between serum hs-CRP and various features of metabolic syndrome. The addition 
of serum hs-CRP to the present definition of the metabolic syndrome may help to identify patients at high risk 
for future cardiovascular disease.  
Keywords: Abdominal obesity, Metabolic syndrome, High sensitive C-reactive protein.  
 
Introduction  
It is well known that obesity is detrimental to health. The abdominal obesity (also known as central obesity, 
central adiposity) means that most of the excess fat is located in the abdominal area. It is the most serious form 
of obesity and is strongly associated with cardiovascular disease (Pérez et al., 2007; Gelber et al., 2008; Zalesin 
et al., 2008), diabetes mellitus ( Wang et al., 2005), some types of cancer (Folsom et al., 2000), psoriasis (Setty 
et al., 2007), adverse pregnancy outcomes (Wendland et al., 2007), earlier mortality in old age (Price et al., 
2006) and many other health conditions. Furthermore, it is also a component of the metabolic syndrome for most 
definitions (Grundy et al., 2005).  
Adipose tissue produces and releases a variety of proinflammatory and anti-inflammatory factors, 
including the adipokines; leptin, adiponectin, resistin, and visfatin, as well as cytokines and chemokines such as 
TNF-α, IL-6 (that stimulates the liver to produce and release C-reactive protein [CRP]), monocyte chemo 
attractant protein-1, and others. Proinflammatory molecules produced by adipose tissue have been implicated as 
active participants in the development of insulin resistance and the increased risk of cardiovascular disease 
associated with obesity. 
Metabolic syndrome is defined as the clustering of multiple metabolic risk factors that increase the risk 
of cardiovascular diseases, type 2 diabetes and all-cause mortality (Meigs, 2000; Laaksonen et al., 2002; Lakka 
et al., 2002). However, currently, there is no accepted criterion for the diagnosis of metabolic syndrome. The 
National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) identifies various 
components of metabolic syndrome in adults and defines it as having three or more of the following: abdominal 
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obesity (waist circumference ≥102 cm for men and ≥88 cm for women), triglyceride levels ≥150 mg/dl, high-
density lipoprotein (HDL) cholesterol ≤ 40 mg/dl for men and ≤ 50 mg/dl for women, blood pressure ≥130/ 85 
mm Hg, and fasting plasma glucose ≥100 mg/dl (Grundy et al., 2004). Other organizations, such as the World 
Health Organization (Alberti and Zimmet , 1998), the European Group for the Study of Insulin Resistance 
(Balkau and Charles, 1999) the American College of Endocrinology (Einhorn et al., 2003) , and the International 
Diabetes Federation (Alberti et al., 2005) have also proposed a criteria for the diagnosis of the metabolic 
syndrome, keeping in common the general features of a combination of central obesity, elevated blood pressure, 
dyslipidemia, and impaired glucose metabolism.  
Findings from the Hispanic Health and Nutrition, metabolic syndrome is also considered as a 
proinflammatory state ( Grundy et al.,2004), and measurement of inflammatory markers like high-sensitivity C-
reactive protein (hs-CRP) (Ridker et al., 2004) might improve the prediction of cardiovascular disease and 
diabetes in patients with metabolic syndrome. Previous studies showed that CRP is associated with components 
of metabolic syndrome (Festa et al., 2000), and including abdominal obesity (Dandona et al., 2005). Cytokine 
production by adipocytes might mediate the elevation of CRP levels. 
The aim of this study is to: 
1- Evaluate the application of hs-CRP to discriminate those with metabolic syndrome from those without 
metabolic syndrome in a population with central obesity. 
2- Evaluate the association between serum hs-CRP level and number of components of metabolic syndrome. 
3- Evaluate the role of High sensitive C-reactive Protein for prediction of Cardiovascular risk level in Metabolic 
Syndrome patients In Sulaimania. 
 
Materials and Methods 
2.1. Subjects and sample collection 
2.1.1. Subjects 
This randomized cross sectional based study was approved by the Scientific Committee of the Hawler Medical 
University at the  College of Pharmacy. The patients were recruited from Endocrinology Centre of Sulaimani at 
Sulaimania governorate-Kurdistan Region-Iraq over a period from May to September 2012. A verbal consent 
form was obtained from each participant prior to admission into the study. 
2.1.2. Criteria of inclusion  
Every centrally obese people from both genders (male and female) aged between twenty to eighty years. Central 
obesity is defined as measured waist circumference (≥ 88 cm in women; ≥ 102 cm in men). Obese peoples 
already on drug treatment for diabetes and hypertension were considered as diabetic and hypertensive 
respectively. 
2.1.3. Criteria of exclusion 
Patients with evidence of acute infections, chronic inflammatory disorders and autoimmune diseases were 
excluded from the study. Also patients with serum hsCRP >10 mg/L have been excluded. 
A total number of one hundred and forty patients were admitted into the study and fulfill the above 
criteria of inclusion and exclusion. Each Patient was subjected to physical examination, determination of blood 
pressure and anthropometric measurements. Three measurements of blood pressure (systolic and diastolic) were 
obtained from the right arm of the patient in sitting position after 30 minutes of resting at five minutes intervals 
and their average values were calculated. The anthropometric measurements included weight (kg), height (m), 
waist circumference (cm) and calculated body mass index. The waist circumference (cm) was measured with a 
soft tape measurement on standing position, midway between the lowest rib and the iliac crest. Body mass index 
(BMI) was calculated using Quetlett's equation: 
BMI (kg/m
2
) =   
Then the patients were subjected to the laboratory investigations including the determination of fasting 
serum glucose and lipid profile, and hs-CRP. 
Metabolic syndrome (MetS) was defined by the criteria of the NCEP ATP III. The diagnosis was made 
when at least three of the five following criteria were present: waist circumference ≥ 88 cm (women) or ≥ 102 
cm (men); triglycerides ≥ 150 mg/dl; HDL cholesterol < 50 mg/dl (women) or < 40 mg/dl (men); blood pressure 
≥ 130/≥ 85 mmHg; fasting glucose ≥ 100 mg/dl. (individuals on antihypertensive, hypoglycemic agents expected 
as hypertensive & diabetic respectively). 
Then the patients were classified into two groups; metabolic group and non-metabolic group. 
 
3. Results 
3.1. Distribution of participants according to the number of MetS components: 
A total number of 140 patients fulfilling the criteria of inclusion were admitted in the study. From these 140 
obese peoples; 8 (5.7%) have one MetS component ; 31(22.1) have two MetS components; 38(27.1) have three   
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MetS components; 51(36.4) have four MetS components; and 12(8.6%) have five  MetS components ( Figure 
3.1). 
 
Figure 3.1. Distribution of participants according to the number of Metabolic Syndrome components. 
 
3.2. Distribution of cases according to the evidence of MetS: 
metabolic syndrome was evident in 72.1% (101 out of 140) with the existence of 3 or more MetS components 
whereas 27.9% (39 out of 140) were non metabolic (Figure 3.2).  
 
Figure 3.2. Distribution of cases according to the evidence of Metabolic Syndrome. 
 
3.3. Distribution of participants according to the gender:  
Female gender comprised 70.7% (99 out of 140) of total participants and 70.7% of them (70 out of 99) were 
MetS while 29.3% (41 out of 140) were men and 75.6% of them (31 out of 41) were MetS (Table 3.1). 
Sex Frequencies Percentages Non Mets N (%) MetS  N(%)  P values 
Male 41 29.3 10(24.4) 31(75.6) 
0,55 Female 99 70.7 29(29.3) 70(70.7) 
Total 140 100 39 (27.9) 101(72.1)   
The results are expressed as number (%) 
Table 3.1 Distribution of participants according to the gender 
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3.4. Serum hs CRP level in both (metabolic & non metabolic) groups: 
The mean+SD hs-CRP value of the participants  without MetS was 1.75+1.530 mg/L compared with 3.64+2.760 
mg/L in the group with MetS, and there is a significant differences between them (p= 0.0001) (Table 3.2).  
 
Mean 
Mg/L 
+S D  
Mg/L 
95% Confidence Interval for Mean 
P values 
Lower limit Upper limit 
HsCRP 
Non MetS 
MetS 
1.75 
3.64 
1.530 
2.760 
1.25 
3.10 
2.24 
4.19 
0.0001 
Table 3.2 Serum high sensitive C-reactive protein level in both (metabolic & non metabolic) groups 
 
3.5. The mean age of patients in respect of the number of metabolic syndrome components:  
The mean age of patients tended to be increased as the number of MetS component increased up to four and five 
(Figure 3.3).  
 
Figure 3.3 The mean age of patients in respect of the number of metabolic syndrome components 
 
3.6. Anthropometric measurements:  
Table3.3 showed the anthropometric measurement of patients enrolled in the study. The mean values of BMI 
showed that all the patients were overweight (one component MetS) or obese (Two, three, four and five 
components MetS). Central obesity assessed by measuring the waist circumference was observed in all patients. 
 One 
Component  
(n=8) 
Two 
Component  
(n=31) 
Three 
Component  
(n=38) 
Four 
Component  
(n=51) 
Five 
Component  
(n=12) 
Weight (kg) 
Height (m) 
BMI (kg/m
2
) 
Waist 
circumference(cm) 
76.62±4.43 
1.606±0.108 
29.88±2.704 
97.37±5.90 
 
76.32±12.06 
1.587±0.085 
30.28±4.14 
98.74±7.65  
81.73±14.20 
1.592±0.094 
32.24±5.358 
104.68±9.63 
86.27±16.36 
1.616±0.092 
32.92±5.23 
106.94±10.29 
87.75±15.51 
1.604±1.105 
33.92±3.64 
107.0±9.72 
The results are expressed as mean ± SD  
Table 3.3 Anthropometric measurements 
 
3.7. Correlations between waist circumference and number of MetS components:  
The mean value of waist circumference tended to be increased with increasing the number of MetS components 
This increment tended to be significantly (p<0.001)  positively correlated (r=0.945)(Figure 3.4).  
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Figure 3.4 Correlations between mean value of waist circumference and number of metabolic syndrome 
components. Each point represents the mean value of number of patients. 
 
3.8. Blood pressure measurements      
The means of systolic and diastolic blood pressures were within normal range. This indicates that the presence of 
high blood pressure as a component of metS was sporadically distributed. 
 Component (1) 
(n=8) 
Component (2) 
(n=31) 
Component (3) 
(n=38) 
Component (4) 
(n=51) 
Component (5) 
(n=12) 
Blood pressure 
(mmHg) 
Systolic 
Diastolic 
 
 
118.75±3.535 
78.75±3.535 
 
 
 
108.38±12.13 
73.70±11.39 
 
 
 
117.36±17.19 
76.84±12.32 
 
 
 
118.43±13.61 
76.56±10.83 
 
 
 
120.0 ±17.58 
80.83±11.64 
 
The results are expressed as mean ± SD 
Table 3.4 Blood pressure measurements 
 
3.9. Fasting serum Lipid profile measurements:  
Table 3.5 shows the mean values of lipid profile in centrally obese patients presented with evidence of metabolic 
syndrome. 
 Component 
(1) 
(n=8) 
Component 
(2) 
(n=31) 
Component 
(3) 
(n=38) 
Component (4) 
(n=51) 
Component 
(5) 
(n=12) 
Cholesterol 
Triglycerides 
HDL 
LDL 
VLDL 
TG/HDL ratio 
173.75±32.5 
112.25±29.21 
45.25±4.13 
106.05±33.13 
22.45±5.84 
2.483±0.644 
151.67±28.55 
106.77±26.35 
43.45±10.51 
86.87±26.36 
21.35±5.27 
2.564±0.796 
156.1±36.55 
153.65±87.10 
40.10±9.59 
85.34±33.87 
30.73±17.42 
4.004±2.322 
159.66±37.47 
211.54±100.25 
34.39±8.13 
82.96±41.68 
42.30±20.05 
6.440±3.900 
153.08±23.73 
229.33±60.09 
28.66±6.154 
78.55±23.37 
45.86±13.81 
8.234±2.581 
The results are expressed as mean ± SD. HDL; high density lipoprotein, LDL; low density lipoprotein, VLDL; 
very low density lipoprotein 
Table 3.5 Fasting serum Lipid profile measurements 
 
3.10. Correlations between number of MetS components and HDL: 
The fasting serum HDL tended to be significantly and negatively correlated with number of components of MetS  
(Figures.3.5 ). 
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Figure 3.5 Correlations between number of metabolic syndrome components and mean value of HDL. 
Each point represents the mean value of number of patients. 
 
3.11. Correlations between number of Mets components and LDL: 
The fasting serum LDL tended to be significantly and negatively correlated with number of components of MetS  
(Figures.3.6 ). 
 
Figure 3.6  Correlations between number of metabolic syndrome components and mean value of  LDL . 
Each point represents the mean value of number of patients. 
 
3.12. Correlations between number of MetS components and atherogenic index: 
Significant positive (direct) correlation between fasting serum triglycerides and atherogenic index with the 
number of MetS components were observed (Figures 3.7). 
 
Figure 3.7 Correlations between number of metabolic syndrome components and mean value of  
atherogenic index. Each point represents the mean value of number of patients. 
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3.13. Correlations between number of MetS components and Triglyceride: 
Significant positive (direct) correlation between fasting serum triglycerides and atherogenic index with the 
number of MetS components were observed (Figures 3.8). 
 
Figure 3.8 Correlations between number of metabolic syndrome components and mean value of  
triglycerides . Each point represents the mean value of number of patients. 
 
3.14. Correlations between number of MetS components and fasting blood glucose: 
The mean value of fasting blood sugar  increased with an increase in the number of  MetS components to reach a 
diabetic level values (Figure 3.9). 
 
Figure 3.9 Correlations between number of metabolic syndrome components and fasting blood glucose 
 
3.15. Correlations between the mean serum level of hs-CRP level of each component number and the 
component numbers of MetS: 
Serum level of hs-CRP increased significantly with a rise in the number of MetS components and it amounts 
0.987±0.438, 1.943±1.651, 3.083±2.774, 3.934±2.713, 4.180±2.842 mg/L for one, two, three, four and five 
components of metabolic syndrome respectively. Taking in consideration the regression equation of best fit line, 
for each one component increment there is an increase of 0.821 mg/L hs-CRP (Figure 3.10).  
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Figure 3.10 Correlations between the mean serum level of hs-CRP level of each component number and 
the component numbers of metabolic syndrome 
 
3.16. Correlations between body mass index and serum hs-CRP level: 
Significant positive correlation between hs-CRP and anthropometric measurements related to the obesity. We 
observed that the hs-CRP was significantly correlated with body mass index (Figure 3.11). 
 
Figure 3.11 Correlations between body mass index and serum hs-CRP level. 
 
3.17. Correlations between waist circumference and serum hs-CRP level: 
Hs-CRP significantly directly correlated with  waist circumference (Figure 3.12). 
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Figure 3.12 Correlations between waist circumference and serum hs-CRP level. 
 
3.18. Correlations between mean arterial blood pressure and serum hs-CRP level:  
Figure 3.13 shows non significant negative correlation between the serum level of hs-CRP and the mean arterial 
blood pressure (mean arterial blood pressure= diastolic blood pressure  (systolic blood pressure –diastolic 
blood pressure).  
 
Figure 3.13 Correlations between mean arterial blood pressure and serum hs-CRP level 
 
3.19. Correlations between serum high density lipoprotein level and serum hs-CRP level: 
The serum level of hs-CRP is significantly and negatively correlated with high density lipoprotein level (Figure 
3.14).  
 
Figure 3.14 Correlations between serum high density lipoprotein level and serum hs-CRP level. 
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3.20. Correlations between serum triglycerides level and serum hs-CRP level: 
Non-significant positive  correlation  between  serum triglycerides level and hs-CRP (Figure 3.15). 
 
Figure 3.15 Correlations between serum triglycerides level and serum hs-CRP level 
 
3.21. Correlations between atherogenic index and serum hs-CRP level: 
Atherogenic index as a marker of cardiovascular risk factor is directly and significantly correlated with hs-CRP 
(Figure 3.16). 
 
Figure 3.16 Correlations between atherogenic index and serum hs-CRP level 
 
3.22. Patients at cardiovascular events risk with respect to high sensitive C-reactive protein and number 
of components of metabolic syndrome: 
Table 3.6 shows the importance of measurement of serum hs-CRP in obese subjects. All the obese participants 
were at risk of cardiovascular events; 20.7% were at low risk; 41.4% were at average risk; and 37.86% were at 
high risk. On the other hand, as the number of components of metabolic syndrome increased the level of hs-CRP 
increased and the risk status also increased.   
Hs CRP level Number of components of metabolic 
syndrome 
Total 
1 2 3 4 5 
Low risk 0-1.0 mg/L  5 8 8 7 1 29 (20.7%) 
Moderate  risk 1.0–3.0 mg/L 3 18 17 15 5 58 (41.4%) 
High risk 3.0–10.0 mg/L 0 5 13 29 6 53 (37.86%) 
Total 8 31 38 51 12 140 (100%) 
The results are expressed as number (percent) 
Table 3.6 Shows the patients at cardiovascular events risk in respect to high sensitive C-reactive protein 
and number of components of metabolic syndrome 
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4. Discussion 
The results of this study demonstrate the importance of measuring the level of hs-CRP in metabolic syndrome as 
well as its significant association with the other components of metabolic syndrome. 
The close relationship between abdominal obesity, metabolic disturbances and cardiovascular disease is 
apparent for clinicians (Santos et al., 2005; Gonzalez et al., 2006; Dupuy et al., 2007; Zuliani et al., 2009; 
Kressel et al., 2009;) . 
Adipose tissue is not just a storage facility for fatty acids. It is an active endocrine organ, producing 
bioactive proteins named adipokines (Winkler et al., 2003; Trayhurn, 2005). Adipokines include interleukin-6, 
adiponectin, resistin, adipsin, tumor necrosis factor-alpha, plasminogen activator-inhibitor-1 and many more. 
Adipokines involved in a multitude of processes like inflammation, insulin resistance, lipid metabolism, 
blood pressure, macrophage infiltration, fibrinolysis, food intake, fat mass regulation and more (Hajer et al., 
2008). 
Cytokines/Adipokines associated with low-grade inflammation were interleukin-6 and tumor necrosis 
factor-alpha, and these are shown to be up-regulated in obese patients (Winkler et al., 2003). 
Studies showed that levels of CRP are significantly related to levels of IL-6 and TNF-apha (Yudkin et 
al., 1999). Interleukin-6 is the chief stimulator of CRP production. Abdominal adipose tissue, with its increased 
production of cytokines from both immune cells and adipocytes, is drained directly to the portal circulation. It 
could be that this direct route to the liver, where CRP is produced, is partly responsible for the increased 
production of CRP in abdominally obese people (Hajer et al., 2008). 
Metabolic syndrome is a clustering of risk factors for diabetes and cardiovascular disease, and 
abdominal obesity is a central feature in this syndrome. The syndrome is recognized as both a proinflammatory 
and prothrombotic state, but the cause of this is not yet fully understood (Reaven , 1988; Imayama et al., 2012; 
Illán-Gómez et al., 2012). 
High sensitive -CRP is the most extensively studied inflammatory biomarker in cardiovascular disease. 
MetS seems to be a proinflammatory state characterized by increased concentrations of CRP. Several earlier 
studies have shown that high CRP concentrations predict the development of diabetes. CRP is shown to impair 
insulin signaling (D’Alessandris et al., 2007). Although increased CRP concentrations correlate most strongly 
with adiposity and insulin resistance, CRP also correlates significantly with the other features of MetS (Yudkin 
et al., 1999; Hak et al., 1999; Festa et al., 2000). Furthermore, CRP concentrations anticipate increased 
cardiovascular events in MetS and in diabetes (Ridker et al., 2003; Rutter et al., 2004; Aguilar et al., 2006; 
Linnemann et al., 2006). 
In this study metabolic syndrome was detected in 101 patients (72.1%) with respect to NCEP ATP III 
definition. 
 
4.1.   Effect of  Metabolic syndrome on the level of serum hs-CRP: 
The mean of hs-CRP levels were significantly higher in individuals with central obesity with the MetS compared 
to individuals with central  
obesity without the MetS. 
The Results of this study are in line with several studies demonstrating higher hs-CRP levels in 
individuals with the MetS (Hak et al., 1999; Festa  et al., 2000; Ridker et al., 2003; Rutter et al., 2004; Lee et al., 
2004; Santos et al., 2005; Gonzalez et al., 2006; Dupuy et al., 2007; Zuliani et al., 2009; Kressel et al., 2009; 
Mahajan et al., 2012). 
 
4.2. Correlations between components of MetS and serum hs-CRP: 
The means of hs-CRP levels increased with the increasing number of MetS components and our results are 
concordant with other studies which displayed a linear increase in hs-CRP levels with the rising number of 
components of the MetS described previously (Hak et al., 1999; Festa  et al., 2000; Frohlich et al., 2000; Ridker 
et al., 2003; Rutter et al., 2004; Lee et al., 2004; Aronson et al., 2004; Santos et al., 2005; Gonzalez et al., 2006; 
Zuliani et al., 2009; Mahajan et al., 2012) . 
As the metabolic syndrome has several components, it could be stated that hs-CRP elevation is related 
to just one or some of these components. Several studies assessed the relation between hs-CRP and different 
MetS components; the results of our study is in a covenant with a number of univariable analyses showing 
significant associations for the individual MetS components(Festa  et al., 2000; 
Ridker et al., 2003; Rutter et al., 2004; Lee et al., 2004; Santos et al., 2005; Gonzalez et al., 2006; 
Dupuy et al., 2007; Zuliani et al., 2009). 
Further multivariable analyses; adjusting for other MetS components, reported that central obesity was 
the major determinant of elevated hs-CRP levels in individuals with the MetS. The other MetS components do 
not, or only marginally, increase hs-CRP level (Aronson et al., 2004; Santos et al., 2005; Florez et al., 2006; 
Dupuy et al., 2007; Zuliani et al., 2009; Lu et al., 2010). This might explain why hs-CRP cannot be used to 
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predict the presence of the MetS. Nevertheless, researchers have proposed to add hs-CRP biomarker as a clinical 
criterion for the metabolic syndrome (Ridker et al., 2004). The reasons could be that it is shown to be a 
consistent prognosticator of cardiovascular and diabetes risk, and is practical in clinical settings. 
The relationship between central obesity and increased levels of hs-CRP is well studied. Adipose tissue 
is known to secrete cytokines that stimulate the production of hs-CRP in the liver, but adipose tissue itself may 
also secrete hs-CRP and thereby raise hs-CRP levels (Ouchi et al., 2003). Genetic polymorphisms could partially 
explain the inter-individual variability observed in the inflammatory profile of obese patients and the inter-
individual variability in metabolic perturbations associated with obesity (Bouchard et al., 2007; Faucher et al., 
2012). 
Strong associations between CRP and measures of body fat (BMI and waist circumference) and 
measures of insulin resistance (insulin sensitivity index, fasting insulin, and proinsulin) were reported (Yudkin et 
al., 1999; Festa  et al., 2000; Ridker et al., 2003; Rutter et al., 2004). 
Although central obesity (waist circumference) and BMI seem to be the major determinant of elevated 
hs-CRP levels in the MetS, significant independent associations between hs-CRP and other components were 
found .  Aronson et al., 2004 found an independent association between triglyceride level and hs-CRP (however, 
in our study we have found a non significant relation between hs-CRP and serum triglyceride) . In addition, they 
found associations between hs-CRP and glucose level and HDL cholesterol (our results have showed agreements 
with this results). However, this only accounted for ~1% of the variability in CRP levels (Aronson et al., 2004). 
Weight loss is shown to decrease CRP levels in obese subjects (Illán-Gómez et al., 2012; Imayama et 
al., 2012), which could support the theory that the adipose tissue is actively involved in the low-grade 
inflammatory state seen in abdominally obese people. Increased levels of CRP is found in obese people. 
A cross sectional study on nondiabetic subjects done by (Yudkin et al., 1999) showed that levels of 
CRP were correlated with all measures of obesity. CRP-levels were also related to insulin resistance, blood 
pressure, HDL, and triglycerides and markers of endothelial dysfunction. Yudkin et al (1999) suggested that 
adipose tissue is an important determinant of low-grade chronic inflammation, and that chronic low-grade 
inflammation may induce insulin resistance and endothelial dysfunction. They also stated that this could be a 
possible link between insulin resistance and endothelial dysfunction and obesity & cardiovascular disease 
(Yudkin et al., 1999). 
A Tunisian case control study found that waist circumference was a significant independent predictor of 
elevated CRP levels in both men and women with metabolic syndrome (Belfki et al., 2012). Also, HDL-C was 
another significant predictor of elevated CRP levels in women only. 
Further cross sectional study found that hs-CRP correlated significantly with all the components of the 
syndrome in both men and women, but the highest correlation was between waist circumference and hs-CRP 
(Rogowski et al., 2010). These findings suggested that waist circumference is the Metabolic component of the 
syndrome that influences the low-grade inflammatory response. They also pointed out that overweight and obese 
individuals without the syndrome were at an increased risk for cardiovascular disease. 
A cross-sectional study done in the Netherlands evaluated the use of hs-CRP to discriminate between 
centrally obese people with and without the syndrome (Engelsen et al., 2012). They found that hs-CRP has 
limited capacity to predict the presence of the metabolic syndrome in people with central obesity. The mean hs-
CRP levels were significantly higher in people with abdominal obesity with the metabolic syndrome than 
without it. As the numbers of components of the syndrome increased, so did the mean hs-CRP levels. Only waist 
circumference and triglyceride levels showed a significant independent association with hs-CRP. They 
concluded that the degree of central obesity seemed to be the main determinant of increased hs-CRP levels. The 
levels of hs-CRP were higher in centrally obese people with the syndrome than those without it, but it could not 
be used to diagnose centrally obese people with the metabolic syndrome in this study. Moreover, further studies 
found an independent association between hs-CRP and fasting glucose (Gonzalez et al., 2006; Niehoff et al., 
2007). 
Other Studies have also concluded that hs - CRP positively correlated with atherogenic index (Altan et 
al., 2010; Idemudia and Idogun , 2012) and this is in agreement with the results of and supports the current study 
Atherogenic index can be easily calculated from standard lipid profile. As a marker of lipoprotein 
particle size it adds predictive value beyond that of the individual lipids, and/or TG/HDL-C ratio  (Dobiásová, 
2006). 
 
4.3. Hs-CRP as a predictor of risk level for future CVD:     
All the obese participants were at risk of cardiovascular events;. On the other hand, as the number of components 
of metabolic syndrome increased the level of hs-CRP increased and the risk status also increased and this is in 
concordance with the results of German population-based study found that there was a positive trend in levels of 
CRP with increasing numbers of components of the metabolic syndrome using BMI and not waist 
circumference,. The age-adjusted geometric means (rather than arithmetic) mean of CRP concentrations in 
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subjects grouped according to the presence of 0-1,1- 3 and > 3 features of the metabolic syndrome were 1.11, 
1.27, and 2.16 mg/L, respectively, (Frölich et al., 2000). 
 
Conclusions 
Emerging laboratory and clinical evidence in participants with central obesity which were involved in this study 
have provided: 
1. The degree of central obesity (waist circumference ) and BMI seemed to be the main determinant of an 
increased hs-CRP level. 
2. The serum hs-CRP was significantly correlated with the presence of metabolic syndrome, meaning that there 
is a strong relationship between serum hs-CRP and various features of metabolic syndrome 
3. The addition of serum hs-CRP to the present definition of the Mets may help identify patients at high risk for 
future CVD.  
4. According to the serum level of hs-CRP that was demonstrated in this study, all the patients are at risk of 
cardiovascular events. 
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